Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Freedberg

Showing results (131-140 of 324) with videos related to

Pageof 33
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2018
Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectivenessLiem B Luong Nguyen, Yazdan Yazdanpanah, David Maman, et al.
Antiviral Therapy|December 25, 2012
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV diseaseBruce R Schackman, David W Haas, Jessica E Becker, et al.
Annals of Internal Medicine|January 16, 2013
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United StatesRochelle P Walensky, Paul E Sax, Yoriko M Nakamura, et al.
Plos One|April 30, 2013
Factors associated with self-reported repeat HIV testing after a negative result in Durban, South AfricaSusan Regan, Elena Losina, Senica Chetty, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2012
The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South AfricaJulie H Levison, Robin Wood, Callie A Scott, et al.
Cost Effectiveness and Resource Allocation : C/E|September 21, 2012
Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availabilityApril D Kimmel, Stephen C Resch, Xavier Anglaret, et al.
Journal of the International AIDS Society|May 15, 2026
Long-Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost-Effectiveness AnalysisWanyi Chen, Paula M Luz, Anjali Srinivasan, et al.
HIV Clinical Trials|December 4, 2010
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax, Caroline E Sloan, Bruce R Schackman, et al.
The Journal of Infectious Diseases|October 14, 2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United StatesEthan D Borre, Emily P Hyle, A David Paltiel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2007
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with menAlethea W McCormick, Rochelle P Walensky, Marc Lipsitch, et al.
Pageof 33

Showing results (131-140 of 324) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2018
Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectivenessLiem B Luong Nguyen, Yazdan Yazdanpanah, David Maman, et al.
Antiviral Therapy|December 25, 2012
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV diseaseBruce R Schackman, David W Haas, Jessica E Becker, et al.
Annals of Internal Medicine|January 16, 2013
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United StatesRochelle P Walensky, Paul E Sax, Yoriko M Nakamura, et al.
Plos One|April 30, 2013
Factors associated with self-reported repeat HIV testing after a negative result in Durban, South AfricaSusan Regan, Elena Losina, Senica Chetty, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2012
The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South AfricaJulie H Levison, Robin Wood, Callie A Scott, et al.
Cost Effectiveness and Resource Allocation : C/E|September 21, 2012
Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availabilityApril D Kimmel, Stephen C Resch, Xavier Anglaret, et al.
Journal of the International AIDS Society|May 15, 2026
Long-Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost-Effectiveness AnalysisWanyi Chen, Paula M Luz, Anjali Srinivasan, et al.
HIV Clinical Trials|December 4, 2010
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax, Caroline E Sloan, Bruce R Schackman, et al.
The Journal of Infectious Diseases|October 14, 2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United StatesEthan D Borre, Emily P Hyle, A David Paltiel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2007
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with menAlethea W McCormick, Rochelle P Walensky, Marc Lipsitch, et al.
Pageof 33